198 related articles for article (PubMed ID: 29651369)
1. Unusual Relapse of Chronic Lymphocytic Leukemia After Remission.
Rizvi W; Truong Q
Cureus; 2018 Feb; 10(2):e2176. PubMed ID: 29651369
[TBL] [Abstract][Full Text] [Related]
2. Leptomeningeal Carcinomatosis in Chronic Lymphocytic Leukemia: A Case Report and Review of the Literature.
Naydenov AV; Taylor LP
Oncologist; 2019 Sep; 24(9):1237-1245. PubMed ID: 30842245
[TBL] [Abstract][Full Text] [Related]
3. Chronic Lymphocytic Leukemia With Leptomeningeal Involvement Presenting as an Acute Encephalopathy.
Bae WH; Yee M; Song L; Canonico MM; Verhoef PA; Shimabukuro KA
Perm J; 2022 Jun; 26(2):126-131. PubMed ID: 35933656
[TBL] [Abstract][Full Text] [Related]
4. Refractory Chronic Lymphocytic Leukemia with Central Nervous System Involvement: A Case Report with Literature Review.
Nakanishi T; Ito T; Fujita S; Satake A; Konishi A; Hotta M; Yoshimura H; Nomura S
J Blood Med; 2020; 11():487-502. PubMed ID: 33380856
[TBL] [Abstract][Full Text] [Related]
5. Case Report: Chronic Lymphocytic Leukemia With Recurrent Complement-Mediated Thrombotic Microangiopathy and C3 Glomerulonephritis.
Ma T; Wang H; Su T; Wang S
Front Med (Lausanne); 2022; 9():813439. PubMed ID: 35223908
[TBL] [Abstract][Full Text] [Related]
6. Leptomeningeal disease in chronic lymphocytic leukemia.
Lange CP; Brouwer RE; Brooimans R; Vecht ChJ
Clin Neurol Neurosurg; 2007 Dec; 109(10):896-901. PubMed ID: 17850954
[TBL] [Abstract][Full Text] [Related]
7. Treatment strategy in chronic lymphocytic leukemia with symptomatic central nervous system involvement: A case report.
Dewaide R; Saevels K
Clin Case Rep; 2023 Nov; 11(11):e7965. PubMed ID: 37953895
[TBL] [Abstract][Full Text] [Related]
8. Chronic lymphocytic leukemia/small lymphocytic lymphoma complicated with skin Langerhans cell sarcoma: A case report.
Li SY; Wang Y; Wang LH
World J Clin Cases; 2021 Dec; 9(34):10715-10722. PubMed ID: 35005006
[TBL] [Abstract][Full Text] [Related]
9. A Rare Nephrotic Syndrome Related to Chronic Lymphocytic Leukemia: Focal Segmental Glomerulosclerosis.
Karakus V; Atas U; Uzuntas S; Dere Y; Meteoglu I
Cureus; 2022 Nov; 14(11):e31545. PubMed ID: 36540526
[TBL] [Abstract][Full Text] [Related]
10. Leukemic leptomeningeal involvement in stage 0 and stage 1 chronic lymphocytic leukemia.
Brick WG; Majmundar M; Hendricks LK; Kallab AM; Burgess RE; Jillella AP
Leuk Lymphoma; 2002 Jan; 43(1):199-201. PubMed ID: 11908730
[TBL] [Abstract][Full Text] [Related]
11. Venetoclax: A Novel Therapeutic Agent for CLL with CNS Involvement.
Karbhari N; Lara-Martinez H; Hill JM
Case Rep Oncol; 2022; 15(1):345-350. PubMed ID: 35529288
[TBL] [Abstract][Full Text] [Related]
12. Excellent response of chemotherapy-resistant B-cell-type chronic lymphocytic leukemia with meningeal involvement to rituximab.
Watanabe N; Takahashi T; Sugimoto N; Tanaka Y; Kurata M; Matsushita A; Maeda A; Nagai K; Nasu K
Int J Clin Oncol; 2005 Oct; 10(5):357-61. PubMed ID: 16247665
[TBL] [Abstract][Full Text] [Related]
13. Lyme disease in a patient with chronic lymphocytic leukemia mimics leukemic meningeosis.
Schweighofer CD; Fätkenheuer G; Staib P; Hallek M; Reiser M
Onkologie; 2007 Nov; 30(11):564-6. PubMed ID: 17992027
[TBL] [Abstract][Full Text] [Related]
14. Fludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemia.
Short NJ; Keating MJ; Wierda WG; Faderl S; Ferrajoli A; Estrov Z; Smith SC; O'Brien SM
Cancer; 2015 Nov; 121(21):3869-76. PubMed ID: 26218678
[TBL] [Abstract][Full Text] [Related]
15. Low-dose fludarabine and cyclophosphamide combined with standard dose rituximab (LD-FCR) is an effective and safe regimen for elderly untreated patients with chronic lymphocytic leukemia: The Israeli CLL study group experience.
Herishanu Y; Tadmor T; Braester A; Bairey O; Aviv A; Rahimi-Levene N; Fineman R; Levi I; Yuklea M; Ruchlemer R; Shvidel L; Polliack A
Hematol Oncol; 2019 Apr; 37(2):185-192. PubMed ID: 30756414
[TBL] [Abstract][Full Text] [Related]
16. [Acquired pure red cell aplasia in a patient with B cell chronic lymphocytic leukemia after fludarabine therapy].
Tsuji T; Hirano T; Yamasaki H; Tuda H
Rinsho Ketsueki; 2015 Jun; 56(6):705-10. PubMed ID: 26256883
[TBL] [Abstract][Full Text] [Related]
17. Meningeal involvement in B-cell chronic lymphocytic leukemia: report of two cases.
Wang ML; Shih LY; Dunn P; Kuo MC
J Formos Med Assoc; 2000 Oct; 99(10):775-8. PubMed ID: 11061073
[TBL] [Abstract][Full Text] [Related]
18. Fludarabine may induce durable remission in patients with leptomeningeal involvement of chronic lymphocytic leukemia.
Knop S; Herrlinger U; Ernemann U; Kanz L; Hebart H
Leuk Lymphoma; 2005 Nov; 46(11):1593-8. PubMed ID: 16236614
[TBL] [Abstract][Full Text] [Related]
19. High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by three years of rituximab maintenance.
García-Marco JA; Jiménez JL; Recasens V; Zarzoso MF; González-Barca E; De Marcos NS; Ramírez MJ; Parraga FJP; Yañez L; De La Serna Torroba J; Malo MDG; Ariznavarreta GD; Persona EP; Guinaldo MAR; De Paz Arias R; Llanos EB; Jarque I; Valle MDCF; Tatay AC; De Oteyza JP; Martin EMD; Fernández IP; Martinez RM; Costa MAA; Champ D; Suarez JG; Díaz MG; Ferrer S; Carbonell F; García-Vela JA;
Haematologica; 2019 Nov; 104(11):2249-2257. PubMed ID: 30890600
[TBL] [Abstract][Full Text] [Related]
20. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
Robak T; Lech-Maranda E; Robak P
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
